Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.

Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...

Teva's transformation boosts profit growth and specialty drugs, offering an undervalued opportunity. Click here to read my ...

Teva Pharmaceutical Industries TEVA reported second-quarter 2025 adjusted earnings of 66 cents per share, which beat the ...

U.S. stocks inched higher midday Wednesday, as investors digested upbeat economic data while keeping an optimistic tone ahead of the Federal Reserve's policy decision and a wave of key tech earnings ...